Heart Failure Drug Combo Effects Modeled
A pooled analysis of 38,753 patients from nine trials provides individualized estimates for how combinations of modern heart failure drugs affect blood pressure, kidney function, and potassium levels.
A new analysis published in Nature Medicine provides estimates for the short-term effects of combination heart failure therapies on key clinical parameters. The study pooled data from 38,753 participants across nine randomized trials to model how drug combinations impact systolic blood pressure, kidney function, and serum potassium over 2 to 12 weeks. For a comprehensive view of patient outcomes, clinicians can refer to our detailed stats page.
Researchers developed a model to address common clinical concerns that hinder the initiation of comprehensive medical therapy. According to the source, worries about hypotension, kidney dysfunction, and hyperkalemia are among the most cited reasons for not starting full treatment regimens. The analysis included patients with heart failure with reduced ejection fraction (HFrEF) and those with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF).
Modeled Effects on Blood Pressure
For patients with HFrEF, the model estimated the effects of combining an angiotensin receptor blocker-neprilysin inhibitor (ARNI), a sodium glucose cotransporter-2 inhibitor (SGLT2i), and a steroidal mineralocorticoid receptor antagonist (sMRA). The estimated mean reduction in systolic blood pressure was 9.2 mmHg. The 95% interval ranged from 10.6 to 7.8 mmHg lower.
In patients with HFmrEF or HFpEF, different combinations were analyzed. The estimated mean systolic blood pressure reduction was 5.9 mmHg for SGLT2i plus sMRA therapy. For SGLT2i plus a nonsteroidal MRA (nsMRA), the estimated reduction was 4.8 mmHg.
Impact on Kidney Function and Potassium
The study also quantified effects on estimated glomerular filtration rate (eGFR) and serum potassium. These measures are critical for monitoring patient safety during treatment intensification.
For the triple therapy of ARNI, SGLT2i, and sMRA in HFrEF, the model estimated an eGFR decline of 6.8 ml min-1 m-2. The same combination was associated with a serum potassium increase of 0.30 mmol l-1.
In HFmrEF/HFpEF patients, the combinations showed varying effects. The SGLT2i plus sMRA combination was linked to an eGFR decline of 7.7 ml min-1 m-2 and a potassium increase of 0.34 mmol l-1. The SGLT2i plus nsMRA combination showed an eGFR decline of 6.1 ml min-1 m-2 and a potassium increase of 0.21 mmol l-1.
Summary of Estimated Treatment Effects
The following table summarizes the key estimated mean effects from the model, as reported in the source.
| Heart Failure Type | Therapy Combination | Systolic BP Change (mmHg) | eGFR Change (ml min-1 m-2) | Serum Potassium Change (mmol l-1) |
|---|---|---|---|---|
| HFrEF | ARNI + SGLT2i + sMRA | -9.2 | -6.8 | +0.30 |
| HFmrEF/HFpEF | SGLT2i + sMRA | -5.9 | -7.7 | +0.34 |
| HFmrEF/HFpEF | SGLT2i + nsMRA | -4.8 | -6.1 | +0.21 |
Data and Clinical Application
The analysis, which the authors describe as providing "individualized estimates," is based on patient-level data from trials funded by several major pharmaceutical companies. The source notes that trial data availability is subject to the separate criteria of AstraZeneca, Bayer, Novartis, and Pfizer.
The researchers state their model can estimate the expected treatment effect for any combination of the studied medical therapies. They tested ARNIs, steroidal MRAs, nonsteroidal MRAs, and SGLT2 inhibitors. The work aims to give clinicians a clearer expectation of short-term physiological changes when combining these drugs, which can be considered alongside other clinical factors like a patient's injuries status.
All figures presented include 95% intervals, offering a range of probable outcomes. The study population comprised 16,877 participants with HFrEF and 21,876 with HFmrEF or HFpEF. The source concludes by framing the analysis as a tool to help optimize therapy while managing expectations regarding key safety parameters.
